Bracco Diagnostics Inc. receives U.S. Food and Drug Administration (FDA) approval for use of MultiHance(R) (gadobenate dimeglumine) injection in magnetic resonance imaging of the central nervous system in pediatric patients younger than two years of age

MONROE TOWNSHIP, N.J., Jan. 30, 2018 -- (Healthcare Sales & Marketing Network) -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world's leading companies in the diagnostic imaging business, announced today that the labe... Biopharmaceuticals, Devices, Diagnostics, Radiology, FDA Bracco Diagnostics, MultiHance, gadobenate dimeglumine, magnetic resonance

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043460

Source: HSMN NewsFeed - January 30, 2018 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Marketing | MRI Scan | Pediatrics | Radiology